Search results
Results from the WOW.Com Content Network
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
The PFA-100 (Platelet Function Assay [1] or Platelet Function Analyser [2]) is a platelet function analyser that aspirates blood in vitro from a blood specimen into disposable test cartridges through a microscopic aperture cut into a biologically active membrane at the end of a capillary.
Bleeding time is a medical test done to assess the function of a person's platelets. It involves making a patient bleed, then timing how long it takes for them to stop bleeding using a stopwatch or other suitable devices. The term template bleeding time is used when the test is performed to standardized parameters.
Multiplate multiple electrode aggregometry (MEA) is a test of platelet function in whole blood. [ 1 ] [ 2 ] The test can be used to diagnose platelet disorders, [ 3 ] [ 4 ] [ 5 ] monitor antiplatelet therapy, [ 6 ] and is also investigated as a potential predictor of transfusion requirements and bleeding risk in cardiac surgery.
Side effects of the donation of platelets generally fall into three categories: blood pressure changes, problems with vein access, and effects of the anticoagulant on the donor's calcium level. Blood pressure changes can sometimes cause nausea, fatigue, and dizziness. Venous access problems can cause bruising, referred to as a hematoma.
In cases of reactive thrombocytosis of more than 1,000x10 9 /L, it may be considered to administer daily low dose aspirin (such as 65 mg) to minimize the risk of stroke or thrombosis. [ 11 ] However, in essential thrombocythemia where platelet counts are over 750x10 9 /L or 1,000x10 9 /L, especially if there are other risk factors for ...
Higher platelet transfusion thresholds have been used in premature neonates, but this has been based on limited evidence. [19] There is now evidence that using a high platelet count threshold (50 x 10 9 /L) increases the risk of death or bleeding compared to a lower platelet count threshold (25 x 10 9 /L) in premature neonates. [20]
Once the platelet count has improved, the dose of steroid is gradually reduced while the possibility of relapse is monitored. 60–90 percent will experience a relapse during dose reduction or cessation. [12] [19] Long-term steroids are avoided if possible because of potential side-effects that include osteoporosis, diabetes and cataracts. [20]